Drug Security in BRICS Countries

5 June, 12:15–13:45 Congress Centre, zone D, conference hall D1
Broadcast
Ensuring access to effective and high-quality drugs for patients is one of the top priorities on the drug security agenda in the expanded BRICS region. The main focuses of cooperation among BRICS nations are: biosafety issues; strengthening capacity for the development and production of vaccines; increasing the size of national drug markets and the overall share of BRICS markets in the global context; finding a balance between medicinal sovereignty and the unimpeded mutual supplies of drugs; expanding cooperation in pharmaceutical innovations; combining production and research capabilities; and optimizing regulatory procedures to simplify market access for safe and high-quality biosimilars amidst fair competition and in people’s interests. Given the current level of geopolitical turbulence today, the drug policies of BRICS member countries should focus on developing long-term partnerships. Does the pharmaceutical market of BRICS countries have the potential and effective solutions that will help address the new challenges? How should BRICS states interact to ensure drug security for their citizens? What mechanisms are needed to harmonize this process? What prospects are there for BRICS countries to collaborate on their drug policies?

Broadcast

Image